title: Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum.
abstract: Paradoxical growth of Candida in vitro at echinocandin concentrations exceeding the MIC is well described, but the clinical relevance is unknown. We assessed echinocandin paradoxical effects against Candida bloodstream isolates (BSI) in the presence or absence of human serum and investigated regulatory mechanisms. As determined by broth microdilution, a paradoxical effect was evident for 60% (18/30), 23% (7/30), and 13% (4/30) of Candida albicans BSI exposed to caspofungin, anidulafungin, and micafungin, respectively, at achievable human serum concentrations (≤8 μg/ml). A paradoxical effect was not evident among 34 C. glabrata BSI and was observed only for caspofungin against C. parapsilosis (4%, 1/23). As determined in time-kill studies, a caspofungin paradoxical effect was demonstrated by C. albicans (2/3), C. glabrata (1/3), and C. parapsilosis (1/3), including BSI that were determined to be negative by microdilution. In 50% human serum, a paradoxical effect was eliminated at caspofungin concentrations up to 64 μg/ml for 100% (8/8) of the C. albicans BSI. A caspofungin paradoxical effect was also eliminated by chitin synthase inhibitor nikkomycin Z and at achievable concentrations of calcineurin pathway inhibitors, tacrolimus and cyclosporine. Moreover, these agents were synergistic with caspofungin against 100, 100, and 88% (7/8) of C. albicans, respectively, and exerted their own paradoxical effects. Finally, paradoxical growth was eliminated in C. albicans irs4- and inp51-null mutants, which lack phosphatidylinositol-(4,5)-bisphosphate 5'-phosphatase. Our findings suggest that the paradoxical effect is unlikely to be important in vivo but remains an important tool to study cell wall stress responses. We implicate the Irs4-Inp51 phosphatidylinositol-(4,5)-bisphosphate 5'-phosphatase as a novel regulator of paradoxical growth.
authors.affiliation: Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.
authors.forename: Ryan K
authors.initials: RK
authors.lastname: Shields
authors.forename: M Hong
authors.initials: MH
authors.lastname: Nguyen
authors.forename: Chen
authors.initials: C
authors.lastname: Du
authors.forename: Ellen
authors.initials: E
authors.lastname: Press
authors.forename: Shaoji
authors.initials: S
authors.lastname: Cheng
authors.forename: Cornelius J
authors.initials: CJ
authors.lastname: Clancy
mesh_terms: D000935:Antifungal Agents / Q000494:pharmacology*; D019703:Calcineurin / Q000502:physiology; D002175:Candida / Q000187:drug effects* / Q000254:growth & development; D000077336:Caspofungin; D002686:Chitin / Q000096:biosynthesis; D054714:Echinocandins / Q000097:blood / Q000494:pharmacology*; D005656:Fungal Proteins / Q000502:physiology; D016469:Fungemia / Q000382:microbiology*; D006801:Humans; D055666:Lipopeptides; D008826:Microbial Sensitivity Tests; D048052:Mitogen-Activated Protein Kinase 3 / Q000502:physiology
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D005656:Fungal Proteins; D055666:Lipopeptides; D002686:Chitin; C077339:CEK1 protein, Candida albicans; D048052:Mitogen-Activated Protein Kinase 3; D019703:Calcineurin; D000077336:Caspofungin